• Explore /
  • Poster
  • / Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).

Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).

Abstract Video & Slides Poster

Authors

null

Vania Hungria

Clinica São Germano, São Paulo, Brazil

Vania Hungria , Pawel Robak , Marek Hus , Chengcheng Fu , Vera Zherebtsova , Christopher Ward , Ana Carolina de Almeida , P. Joy Ho , Roman Hajek , Claudio Cerchione , Nicholas Pirooz , Astrid McKeown , Hena Baig , Lydia Eccersley , Farrah Pompilus , Simon McNamara , Chee Paul Lin , Sumita Roy-Ghanta , Joanna Opalinska , Maria-Victoria Mateos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 7543)

DOI

10.1200/JCO.2024.42.16_suppl.7543

Abstract #

7543

Poster Bd #

180

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

First Author: Apar Kishor Ganti

First Author: Michel Delforge

First Author: Richard S. Finn